Hansa Biopharma (SE:HNSA) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hansa Biopharma (SE:HNSA) has updated its Phase 3 trial titled “A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease).” The study aims to see if adding imlifidase to current care can better protect kidney function in patients with this rare and severe autoimmune disease.
The main treatment tested is imlifidase, a drug designed to quickly clear harmful antibodies from the blood. It is given on top of standard care, which includes plasma exchange, cyclophosphamide, and steroids, and is compared with standard care alone to see if outcomes improve.
The trial is an interventional Phase 3 study where patients are randomly placed into one of two groups. It is open-label, meaning doctors and patients know which treatment is given, and the primary purpose is to treat the disease and measure kidney outcomes over time.
The study was first submitted on 15 Dec 2022, setting the starting point for patient enrollment and regulatory review. The most recent update was filed on 2 Mar 2026, and the status now shows as terminated, signaling the trial stopped early and that investors should watch for reasons and any follow-up data.
For investors, the terminated status is a clear setback for Hansa Biopharma’s plans to expand imlifidase into anti-GBM disease and may pressure the stock in the near term. It also weakens a potential new revenue stream in a niche but high-need segment, while reinforcing the relative strength of existing kidney and autoimmune treatment players that still rely on traditional standard of care.
The study has been updated and is no longer enrolling, and investors can find further details on the ClinicalTrials portal.
To learn more about SE:HNSA’s potential, visit the Hansa Biopharma drug pipeline page.